About Translational Drug Development (TD2)
Translational Drug Development (TD2) is a world-class drug development organization specializing in getting the newest and best oncology treatments to cancer patients as quickly as possible.
To focus cutting-edge science into translational solutions. Driven by science and motivated by patients, TD2 strives to make a significant impact on cancer.+
World class preclinical, regulatory and clinical science aligned with unique patient identification and recruitment solutions and the ability to execute with urgency.+
“Development of new medicines requires both the best possible preclinical and clinical science. It also demands working with a great sense of urgency. The TD2 team provides innovative solutions that give new medicines the best chance to work for patients with cancer. With expert capabilities that support early discovery, pharmacokinetics, regulatory affairs and clinical development through Phase II, TD2 represents a comprehensive solution for oncology-focused companies.”
Daniel D. Von Hoff, MD, FACP, Chief Development Officer - TD2
“TD2 has a rich scientific heritage and has successfully identified, translated and applied -omics driven outcomes to speed the development of new oncology medicines, and to identify those cancer patients most likely to have clinical benefit from these new drugs.”
Jeffrey Trent, PhD, FACMG, President and Research Director - Translational Genomics Research Institute (TGen)
Standard therapies for treating cancer include surgery, radiation therapy and chemotherapy, depending on the part of the body affected and stage at which the cancer is diagnosed. Solid tumors respond well to surgery if they are contained or...
November 21, 2016 Ziopharm presents preclinical data generated by TD2; Local Regulated IL-12 Expression as an Immunotherapy for the Treatment of Pontine Glioma. See attached poster....
All clinical trials progress through levels—Phase I, Phase II and Phase III. Phase I of a clinical trial involves studying the new drug or treatment to discover a safe dose amount. Evaluation of the drug’s safety at different...
Please submit your e-mail to subscribe to TD2 news